Ovarian granulosa cell tumours are rare cancers that produce hormones and often cause unusual bleeding or early puberty, but when caught early, treatment outcomes are generally favourable.

How Treatment Helps Women with Granulosa Cell Tumours

When a woman receives a diagnosis of ovarian granulosa cell tumour, understanding treatment options becomes essential for making informed decisions about her care. The primary goals of treatment include removing the tumour completely, managing symptoms caused by high hormone levels, preventing the cancer from spreading, and reducing the risk of recurrence^[1]. Because these tumours grow slowly compared to other ovarian cancers, many patients have time to discuss options carefully with their medical team.

Treatment approaches depend heavily on several factors unique to each patient. The stage of the tumour—meaning how far it has spread—plays the most important role in determining treatment strategy^[9]. A woman’s age and whether she wishes to have children in the future also significantly influence treatment decisions. For younger women who have not completed their families, doctors try to preserve fertility whenever safely possible. Postmenopausal women or those who have finished childbearing typically receive more extensive surgical treatment^[2].

Most granulosa cell tumours are diagnosed at an early stage, with approximately 78 to 91 percent of cases detected when the cancer is still confined to the ovary^[6]. This early detection happens because these tumours produce estrogen, a female sex hormone, which causes noticeable symptoms like irregular menstrual bleeding, bleeding after menopause, or early puberty in young girls^[1]. These hormone-related symptoms often prompt women to seek medical attention before the tumour has grown large or spread beyond the ovary.

Standard Surgical Treatment

Surgery remains the cornerstone of treatment for ovarian granulosa cell tumours. The primary objective during surgery is to remove as much of the tumour as possible while keeping healthy tissue intact—a process doctors call optimal cytoreduction^[10]. For early-stage disease that has not spread beyond the ovary, surgery alone may be the only treatment needed.

The specific surgical approach varies based on the patient’s circumstances. Young women who wish to preserve their ability to have children may undergo unilateral salpingo-oophorectomy, which means removing only the affected ovary and fallopian tube on one side^[9]. The surgeon also performs surgical staging during the procedure, which involves carefully examining the abdomen and pelvis, taking tissue samples, and checking for any signs that the cancer has spread. This fertility-sparing approach is suitable for women with early-stage disease who have not yet completed their families.

For postmenopausal women or those who have finished childbearing, doctors typically recommend more extensive surgery. This usually includes total abdominal hysterectomy (removal of the uterus) and bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes)^[2]. The more comprehensive approach helps reduce the risk of recurrence because granulosa cell tumours can sometimes develop in the other ovary over time, and the high estrogen levels these tumours produce can cause changes in the uterine lining that may become cancerous.

During surgery, doctors use a staging system to determine exactly where the tumour is located and whether it has spread. Stage 1 tumours have not spread outside the ovaries. Stage 2 to 4 tumours have spread to nearby pelvic structures, lymph nodes, or distant organs^[1]. The staging information is crucial because it helps doctors decide whether additional treatment beyond surgery is necessary.

Chemotherapy as Additional Treatment

Not all patients with granulosa cell tumours require chemotherapy. For women diagnosed with early-stage disease confined to one ovary, surgery alone is often sufficient treatment. However, chemotherapy becomes an important consideration for patients with more advanced disease or certain high-risk features^[5].

Doctors recommend chemotherapy for patients with juvenile granulosa cell tumours if the cancer is stage 1C or greater. For adult granulosa cell tumours, chemotherapy is considered when the disease is stage 1C2 or more advanced^[5]. These staging classifications indicate that the tumour has certain features suggesting higher risk, such as rupture before surgery, cells found in abdominal fluid, or spread beyond the ovary’s surface.

When chemotherapy is used, it typically follows standard regimens developed for ovarian cancer. The most common approach uses a combination of drugs including platinum-based agents and other antineoplastic agents—medicines specifically designed to fight cancer cells^[10]. These drugs work by interfering with cancer cells’ ability to grow and multiply.

Research examining the effectiveness of chemotherapy in granulosa cell tumours has shown moderate response rates. According to studies, approximately 30 percent of patients show objective improvement with chemotherapy, while about 58 percent achieve disease control, which includes both tumour shrinkage and preventing further growth^[12]. While these numbers may seem modest, they represent valuable time for patients, potentially delaying the need for additional surgery and maintaining quality of life.

Chemotherapy does come with side effects that patients need to understand before starting treatment. Common side effects can include nausea, fatigue, hair loss, increased risk of infections due to lowered blood cell counts, and neuropathy (tingling or numbness in hands and feet). Doctors prescribe antiemetics (anti-nausea medications) to help manage digestive symptoms and may adjust chemotherapy doses if side effects become severe^[10].

Anti-Hormonal Treatment Options

Because granulosa cell tumours produce hormones—particularly estrogen—researchers have explored whether hormonal treatments might help control these cancers. Anti-hormonal therapy represents a different approach from chemotherapy, targeting the tumour’s hormone-producing characteristics rather than using traditional cancer-killing drugs.

Anti-hormonal regimens include GnRH analogues (medications that affect hormone production) and aromatase inhibitors (drugs that block estrogen production)^[10]. These treatments work by reducing estrogen levels in the body or blocking estrogen’s effects on cells. Since granulosa cell tumours depend on hormonal signals for growth, interfering with these signals may slow tumour progression.

Studies examining anti-hormonal therapy have found that about 11 percent of patients show objective tumour response to these treatments, while approximately 66 percent achieve disease control^[12]. Although the tumour-shrinking effects are less dramatic than with chemotherapy, the disease control rate is actually higher. This means that while anti-hormonal treatments may not make tumours disappear, they can keep them stable for extended periods.

One significant advantage of anti-hormonal therapy is that these medications typically cause fewer and less severe side effects compared to chemotherapy. Patients may experience menopausal symptoms like hot flashes, night sweats, and mood changes, but generally do not face the severe nausea, hair loss, or immune suppression that chemotherapy can cause. This makes anti-hormonal treatment an attractive option, particularly for patients with recurrent disease who wish to maintain better quality of life.

Radiation Therapy for Selected Cases

Radiation therapy is not routinely used for granulosa cell tumours, but it may have a role in specific situations, particularly for patients with recurrent disease limited to the pelvis. Radiotherapy uses high-energy rays to damage cancer cells and stop them from growing^[10].

Historical studies have examined radiation therapy for advanced or recurrent granulosa cell tumours with mixed results. In one study from MD Anderson Cancer Center, six of 14 patients with measurable disease achieved complete clinical responses to pelvic radiation, and three patients remained disease-free for 10 to 21 years after radiation treatment^[10]. However, three patients experienced recurrence four to five years after radiation, and eight patients showed no response to treatment.

More recent research has suggested that radiation therapy might improve survival when used as additional treatment after surgery. One study found that patients receiving radiation had better disease-free survival—251 months compared to 114 months for those not receiving radiation^[10]. However, interpreting these results requires caution because most patients who received radiation had earlier-stage disease to begin with.

Currently, doctors consider radiation therapy an option for patients with advanced-stage disease and for those with pelvic recurrence. Clinical responses occur in approximately half of patients treated with radiation therapy for recurrent disease^[10]. The treatment is typically delivered over several weeks, with patients receiving small doses of radiation daily to minimize damage to healthy tissues.

Treatment in Clinical Trials

Because granulosa cell tumours are rare, accounting for only about 5 percent of ovarian cancers, developing new treatments has been challenging^[1]. Standard chemotherapy regimens borrowed from more common ovarian cancers provide only moderate benefit, leaving room for improvement. This has led researchers to explore innovative approaches specifically designed for these hormone-producing tumours.

Clinical trials represent the frontier of treatment development, testing new drugs and approaches before they become widely available. Understanding how clinical trials work helps patients appreciate what participation might involve. Phase I trials primarily focus on safety, determining what dose of a new drug can be given safely and identifying side effects. Phase II trials examine whether the new treatment shows signs of effectiveness against the cancer. Phase III trials compare the new treatment directly against current standard treatments to see if it works better.

Currently, a major clinical trial called NRG-GY033 is specifically recruiting patients with recurrent adult-type granulosa cell tumours of the ovary^[11]. This trial is significant because few studies have focused exclusively on this rare cancer type. By bringing together patients from multiple centres, researchers hope to gather enough data to understand which treatments work best for recurrent disease.

Researchers are particularly interested in developing targeted therapies that address the specific molecular characteristics of granulosa cell tumours. Scientists have discovered that approximately 97 percent of adult granulosa cell tumours contain an identical mutation in the FOXL2 gene^[3]. This mutation causes an amino acid substitution in the FOXL2 protein, specifically changing one building block (cysteine) to another (tryptophan) at position 134. This near-universal genetic change provides a potential target for developing treatments specifically designed for these tumours.

In addition to the FOXL2 mutation, researchers have identified other genetic changes in granulosa cell tumours that might serve as treatment targets. About 41 percent of these tumours have mutations in the TERT promoter, and this mutation appears more frequently in recurrent tumours than in newly diagnosed ones^[7]. Approximately 14 percent of tumours have truncating mutations in KMT2D, a gene involved in regulating other genes, and about 4 percent have mutations in TP53, a well-known cancer gene^[7].

For juvenile granulosa cell tumours, which occur in younger patients, scientists have discovered a different genetic pattern. More than 60 percent of juvenile tumours occurring in girls under 15 years of age have duplications in the AKT1 gene^[3]. Tumours without these duplications often carry point mutations affecting highly conserved parts of the AKT1 protein. The mutated AKT1 proteins show abnormal location within cells and cause strong activation of growth signals.

Understanding these molecular changes has important implications for developing targeted therapies. Drugs that specifically inhibit the pathways activated by these mutations could potentially provide more effective treatment with fewer side effects than traditional chemotherapy. Researchers are exploring various approaches including inhibitors of signalling pathways, drugs that target hormone receptors, and agents that interfere with processes the tumours need for growth.

One challenge in developing targeted therapies for granulosa cell tumours is that these cancers typically show low tumour mutational burden—meaning they have relatively few genetic mutations overall^[7]. This characteristic makes them less likely to respond to newer immunotherapy treatments that work well in cancers with many mutations. However, it also means that the few key mutations present might be particularly important for driving tumour growth, making them excellent potential targets.

Research continues into understanding the signalling pathways involved in granulosa cell tumour development. Scientists are examining how the FOXL2 mutation and other genetic changes affect cellular processes like folliculogenesis (the development of ovarian follicles), hormone signalling, and cell division^[3]. Identifying which transcription factors (proteins that control gene activity) and signalling molecules are disrupted in these tumours may reveal new treatment targets.

Some researchers are also investigating whether existing drugs developed for other purposes might be repurposed to treat granulosa cell tumours. This approach can accelerate treatment development because these drugs have already been tested for safety in humans. If laboratory studies show that such drugs can slow granulosa cell tumour growth, they could move into clinical trials more quickly than entirely new medications.

Most common treatment methods

• Surgery
  • Unilateral salpingo-oophorectomy for fertility preservation in young women with early-stage disease
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy for postmenopausal women or those who have completed childbearing
  • Surgical staging to determine cancer spread and guide further treatment decisions
  • Optimal cytoreduction to remove as much tumour as possible while preserving healthy tissue
• Chemotherapy
  • Platinum-based chemotherapy regimens for advanced-stage disease
  • Antineoplastic agents that interfere with cancer cell growth and division
  • Used for stage 1C or greater juvenile tumours and stage 1C2 or greater adult tumours
  • Approximately 30% objective response rate with 58% disease control rate
• Anti-hormonal therapy
  • GnRH analogues that affect hormone production pathways
  • Aromatase inhibitors that block estrogen production
  • Approximately 11% objective response rate with 66% disease control rate
  • Generally fewer side effects compared to traditional chemotherapy
• Radiation therapy
  • Pelvic radiation for selected patients with recurrent disease
  • Complete clinical response achieved in some patients with measurable disease
  • Considered an option for advanced-stage patients and those with pelvic recurrence
  • Clinical responses occur in approximately half of treated patients

Follow-Up Care and Long-Term Monitoring

After completing initial treatment, patients enter a surveillance phase that continues for the rest of their lives. This long-term monitoring is essential because granulosa cell tumours have a well-documented tendency to recur years or even decades after apparently successful treatment^[2]. Some patients experience recurrence 20 or 30 years after their initial diagnosis, making lifelong follow-up critical.

Regular follow-up appointments typically include physical examinations, particularly pelvic examinations to check for signs of recurrence. Doctors also monitor tumour markers in blood tests. The most useful marker for granulosa cell tumours is inhibin, a hormone produced by these tumours^[1]. Rising inhibin levels in someone previously treated for granulosa cell tumour can signal recurrence before any symptoms appear or tumours become visible on imaging studies.

Other markers that may be monitored include CA-125, a protein often elevated in various ovarian cancers, and anti-Müllerian hormone (AMH), another substance produced by granulosa cells^[5]. Regular blood tests checking these markers allow doctors to track whether disease remains controlled or shows signs of returning.

When blood tests or physical examinations suggest possible recurrence, doctors typically order imaging studies. CT scans (computed tomography) of the abdomen and pelvis are commonly used to look for recurrent tumours^[10]. MRI (magnetic resonance imaging) provides detailed images of soft tissues and may be used in some cases. PET scans (positron emission tomography), which show metabolically active areas, can sometimes detect recurrent disease^[5].

The frequency of follow-up visits typically depends on time since treatment and individual risk factors. Patients may have appointments every three to four months initially, extending to every six months after several years without recurrence. However, because late recurrence is common with these tumours, complete discharge from surveillance never occurs. Patients need regular monitoring throughout their lives to catch any recurrence as early as possible.

Living with and After Treatment

Managing life after treatment for granulosa cell tumour involves addressing both physical and emotional challenges. Women who undergo surgery removing both ovaries before natural menopause will experience sudden surgical menopause, with symptoms including hot flashes, night sweats, mood changes, and vaginal dryness. Doctors may recommend hormone replacement therapy for these women, although this decision requires careful consideration given the hormone-producing nature of the original tumour.

For young women who had fertility-sparing surgery, questions about future pregnancy arise. In general, women who still have one ovary can conceive and carry pregnancies successfully. However, doctors typically recommend waiting until surveillance confirms stable disease for at least one to two years before attempting pregnancy. Some women may benefit from consultation with fertility specialists, particularly if they plan to delay childbearing significantly and want to consider options like egg freezing.

Patients who have had granulosa cell tumours face increased risk for other cancers, particularly endometrial cancer (cancer of the uterine lining) and breast cancer^[1]. The high estrogen levels produced by granulosa cell tumours can cause the endometrial lining to become abnormally thick, a condition called endometrial hyperplasia, which can progress to cancer. Women who kept their uterus after treatment need regular monitoring of the endometrium, sometimes including endometrial biopsies. Regular mammograms for breast cancer screening are also important.

The psychological impact of living with a rare cancer should not be underestimated. Many women feel isolated because their cancer is uncommon and even their doctors may have limited experience with it. Support groups, particularly online communities connecting patients worldwide, can provide invaluable emotional support and practical information. One such group, GCT Survivor Sisters, has brought together patients globally, sharing experiences and contributing to research efforts^[15].

Maintaining overall health through balanced nutrition, regular physical activity, and stress management supports recovery and long-term wellbeing. While no specific diet prevents recurrence of granulosa cell tumours, general healthy eating patterns that support immune function and overall health are beneficial. Regular exercise helps manage weight, reduces stress, and improves mood—all important factors in recovery and long-term survivorship.

Understanding prognosis helps patients set realistic expectations. For early-stage disease, outcomes are generally favourable, with five-year overall survival rates of approximately 85 percent and ten-year survival rates around 73 percent^[9]. Advanced stage at diagnosis is the most important predictor of outcome, with stage being a significant independent prognostic factor for both overall survival and event-free survival^[9].

However, even patients with advanced disease or recurrence can live for many years with appropriate treatment. The slow-growing nature of these tumours means that even recurrent disease can often be managed for extended periods through surgery, chemotherapy, or anti-hormonal therapy. Some patients undergo multiple treatments over years or decades, achieving good quality of life between treatment periods.